Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Iovance Biotherapeutics : Shares Rally 11% After Upgrade From JMP Securities

06/10/2021 | 01:59pm EDT


ę MT Newswires 2021
All news about IOVANCE BIOTHERAPEUTICS, INC.
07:31aIovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL..
GL
08/19IOVANCE BIOTHERAPEUTICS : Corporate Presentation
PU
08/06IOVANCE BIOTHERAPEUTICS : Goldman Sachs Adjusts Price Target for Iovance Biotherapeutics t..
MT
08/06IOVANCE BIOTHERAPEUTICS : Reports Second Quarter and First Half 2021 Financial Results and..
AQ
08/05IOVANCE BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Condition and ..
AQ
08/05Iovance Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter Ended Jun..
CI
08/05IOVANCE BIOTHERAPEUTICS : Q2 Earnings Snapshot
AQ
08/05IOVANCE BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial S..
AQ
08/05IOVANCE BIOTHERAPEUTICS : Reports Second Quarter and First Half 2021áFinancial Results and..
AQ
07/19IOVANCE BIOTHERAPEUTICS : to Host Second Quarter Financial Results Conference Call and Web..
AQ
More news
Analyst Recommendations on IOVANCE BIOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -319 M - -
Net cash 2021 506 M - -
P/E ratio 2021 -11,9x
Yield 2021 -
Capitalization 3 870 M 3 870 M -
EV / Sales 2021 -
EV / Sales 2022 1 022x
Nbr of Employees 241
Free-Float 92,3%
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 24,96 $
Average target price 40,38 $
Spread / Average Target 61,8%
EPS Revisions
Managers and Directors
Frederick G. Vogt President, CEO, Secretary & General Counsel
Jean-Marc Bellemin CFO & Principal Accounting Officer
Iain David Dukes Chairman
Friedrich Graf Finckenstein Chief Medical Officer
Igor P. Bilinsky Chief Operating Officer
Sector and Competitors